CCR5 and breast carcinoma: CCR5–CCL5 axis inhibitors. CCR5 is expressed on different cell types apart from Mф and DCs, including T lymphocytes and cancer cells (i.e., prostate and breast cancer), and mediates numerous functions such as immune suppression and angiogenesis [56].